Aventis’ Estorra Rights Acquired By Private Equity Firm For $115 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is divesting its rights in the insomnia drug as part of a Federal Trade Commission consent agreement clearing the Sanofi merger. Paul Royalty Fund II, an affiliate of Paul Capital Partners, will make fixed and milestone payments.
You may also be interested in...
Sepracor Estorra DTC Campaign Will Follow Product Launch
The direct-to-consumer ads will commence once Estorra's "profile" is known by doctors, Sepracor says. The company plans to at least match the estimated $60 mil. in DTC spend for Sanofi-Aventis' insomnia drug Ambien.
Sepracor Estorra DTC Campaign Will Follow Product Launch
The direct-to-consumer ads will commence once Estorra's "profile" is known by doctors, Sepracor says. The company plans to at least match the estimated $60 mil. in DTC spend for Sanofi-Aventis' insomnia drug Ambien.
Sanofi-Aventis Merger Complete
Sanofi-Aventis launches as the third largest pharmaceutical company in the world following completion of the Sanofi-Synthelabo/Aventis merger